Skip to main content

Table 3 Quality summary: authors’ assessment of risk of bias in randomised controlled trials included in meta-analysis

From: Fenoldopam to prevent acute kidney injury after major surgery—a systematic review and meta-analysis

Author

Random sequence generation

Allocation concealment

Blinding of participants, personnel and outcome assessors

Incomplete outcome data

Selective outcome reporting

Commercial involvement

Other sources of bias

Overall assessment

O’Hara et al. [19]

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Ranucci et al. [17]

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

High riska

High risk

Barr et al. [15]

Unclear

Low risk

Low risk

Low risk

Low risk

Low risk

Low riska

High risk

Cogliati et al. [16]

Low risk

Low risk

Low risk

Low risk

Low risk

Unclear

High riska

High risk

Biancofiore et al. [18]

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

High riska

High risk

Halpenny et al. [5]

Unclear

Unclear

Low risk

Low risk

Low risk

Unclear

High riskb

High risk

  1. Risk of bias was judged by the authors to be high, unclear or low according to the Cochrane Collaboration’s risk of bias assessment tool
  2. aHigh risk due to potential imbalance in number of patients with pre-existing chronic kidney disease
  3. bHigh risk because the definition of AKI was not provided